| ［1］ |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229–263.
|
| ［2］ |
中华医学会肿瘤学分会早诊早治学组. 胃癌早诊早治中国专家共识(2023版)[J]. 中华消化外科杂志, 2024, 23(1): 23–36.
|
| ［3］ |
Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives[J]. J Hematol Oncol, 2023, 16(1): 57.
|
| ［4］ |
Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27–40.
|
| ［5］ |
Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2023, 24(11): 1181–1195.
|
| ［6］ |
Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial[J]. JAMA, 2023, 330(21): 2064–2074.
|
| ［7］ |
Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial[J]. BMJ, 2024, 385: e078876.
|
| ［8］ |
Shen L, Zhang Y, Li Z, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, double-blind, phase 3 trial[J]. Nat Med, 2025, 31(4): 1163–1170.
|
| ［9］ |
Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): An interim analysis of the multicentre, double-blind, randomised phase 3 study[J]. Lancet Oncol, 2024, 25(2): 212–224.
|
| ［10］ |
Li C, Tian Y, Zheng Y, et al. Pathologic response of phase Ⅲ study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON Ⅳ/CAP 05)[J]. J Clin Oncol, 2025, 43(4): 464–474.
|
| ［11］ |
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer[J]. N Engl J Med, 2025, 393(3): 217–230.
|
| ［12］ |
Zhao L, Liu H, Yu J, et al. Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): A multicentre, single-arm, exploratory phase 2 study[J]. EClinicalMedicine, 2025, 87: 103421.
|
| ［13］ |
Sun X, Lyu J, Yang M, et al. Two-year outcomes and biomarker analysis of locally advanced gastric and gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy and immunotherapy from the phase Ⅱ WuhanUHGI001 trial[J]. Ann Surg Oncol, 2024, 31(12): 8157–8169.
|
| ［14］ |
Nie RC, Yuan SQ, Ding Y, et al. Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): A prospective, nonrandomized, open-label, phase 2 trial[J]. Signal Transduct Target Ther, 2025, 10(1): 60.
|
| ［15］ |
Choo J, Sargsyan A, Khachatryan V, et al. Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics[J]. Nat Rev Clin Oncol, 2026, 23(6): 441-458.
|
| ［16］ |
中国抗癌协会胃癌专业委员会, 梁寒, 朱正纲, 等. 基于PD-L1蛋白表达水平的胃癌免疫治疗专家共识(2023年版)[J]. 中国肿瘤临床, 2024, 51(2): 55–63.
|
| ［17］ |
Yeong J, Lum HYJ, Teo CB, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy[J]. Gastric Cancer, 2022, 25(4): 741–750.
|
| ［18］ |
乔旭东, 杜苗苗, 骆瑞闯. 胃充盈超声造影联合血清TGFBI、PD-L1对老年胃癌术前分期的诊断价值[J/OL]. 中华消化病与影像杂志（电子版）, 2025, 15(5): 449-453.
|
| ［19］ |
Chen Z, Ma Y, Chen J. Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives[J]. World J Surg Oncol, 2025, 23(1): 92.
|
| ［20］ |
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(10): 1571–1580.
|
| ［21］ |
André T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase Ⅱ study[J]. J Clin Oncol, 2023, 41(2): 255–265.
|
| ［22］ |
Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J]. Nature, 2021, 600(7890): 727–730.
|
| ［23］ |
Kelly RJ, Landon BV, Zaidi AH, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: A phase Ⅰb trial and ctDNA analyses[J]. Nat Med, 2024, 30(4): 1023–1034.
|
| ［24］ |
Luo D, Zhou J, Ruan S, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies[J]. Cell Death Dis, 2025, 16(1): 75.
|
| ［25］ |
Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development[J]. Trends Cancer, 2024, 10(7): 627–642.
|
| ［26］ |
许建江, 刘涛, 姜雷. PD-1抑制剂治疗胃癌耐药机制的研究进展[J]. 中国肿瘤临床, 2025, 52(4): 188–192.
|
| ［27］ |
Han Z, Cheng S, Dai D, et al. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer[J]. Clin Transl Med, 2023, 13(7): e1312.
|
| ［28］ |
Ling Z, Shao L, Liu X, et al. Regulatory T cells and plasmacytoid dendritic cells within the tumor microenvironment in gastric cancer are correlated with gastric microbiota dysbiosis: A preliminary study[J]. Front Immunol, 2019, 10: 533.
|
| ［29］ |
Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: A review[J]. Front Immunol, 2023, 14: 1167975.
|
| ［30］ |
Karaviti D, Kani ER, Karaviti E, et al. Thyroid disorders induced by immune checkpoint inhibitors[J]. Endocrine, 2024, 85(1): 67–79.
|
| ［31］ |
Di Dalmazi G, Ippolito S, Lupi I, et al. Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment[J]. Expert Rev Endocrinol Metab, 2019, 14(6): 381–398.
|
| ［32］ |
Lin MX, Zang D, Liu CG, et al. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management[J]. Front Immunol, 2024, 15: 1266850.
|
| ［33］ |
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223–249.
|
| ［34］ |
Zeng D, Yu Y, Qiu W, et al. Immunotyping the tumor microenvironment reveals molecular heterogeneity for personalized immunotherapy in cancer[J]. Adv Sci (Weinh), 2025, 12(25): e2417593.
|
| ［35］ |
Janjigian YY, Oh DY, Pelster M, et al. Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: A phase 2 trial[J]. Nat Med, 2025, 31(12): 4274–4280.
|
| ［36］ |
Shitara K, Bang Y J, Iwasa S, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial[J]. Nat Med, 2024, 30(7): 1933–1942.
|
| ［37］ |
Peng Z, Chen P, Lu J, et al. Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial[J]. EClinicalMedicine, 2025, 87: 103404.
|
| ［38］ |
Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study[J]. Lancet Oncol, 2023, 24(7): 744–756.
|